ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

WVE vs GYRE // DIVIDEND YIELD & FCF PAYOUT SAFETY

Wave Life Sciences Inc. (NASDAQ) VS. Gyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: WVE 2 — GYRE 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WVE VS. GYRE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC WVE GYRE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 95.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.40% -60.40 GYRE /roic <GO>
EV/EBITDA & P/E Valuation — 53.3x — TIE /valuation <GO>
Free Cash Flow Yield — -0.03% — TIE /fcf-yield <GO>
Operating Margin -60.00% 9.90% -69.90 GYRE /operating-margins <GO>
Net Profit Margin -60.00% 8.50% -68.50 GYRE /net-margins <GO>
Revenue Growth (YoY) -60.50% 10.20% -70.70 GYRE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.85 14.33 -13.48 GYRE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 GYRE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 29.5 +19.56 WVE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 67.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $715.9M $714.8M $1.2M WVE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR WVE REV GYRE REV WVE GROSS % GYRE GROSS % WVE FCF GYRE FCF
FY 2025 $42.7M $116.6M — 95.4% -$188.2M -$180.0K
FY 2024 $108.3M $105.8M — 96.3% -$152.0M -$6.0M
FY 2023 $113.3M $113.5M — — -$19.4M $25.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WVE // BETA —
GYRE // BETA —